Inovio Pharmaceuticals Inc (NASDAQ:INO) Director Simon X. Benito sold 3,750 shares of the stock in a transaction on Thursday, April 12th. The shares were sold at an average price of $5.23, for a total transaction of $19,612.50. Following the transaction, the director now directly owns 31,548 shares in the company, valued at approximately $164,996.04. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Inovio Pharmaceuticals stock traded down $0.10 during trading hours on Friday, reaching $5.06. The stock had a trading volume of 868,577 shares, compared to its average volume of 1,328,305. The firm has a market cap of $444.43, a PE ratio of -4.64 and a beta of 2.51. Inovio Pharmaceuticals Inc has a 52 week low of $3.76 and a 52 week high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.06. The business had revenue of $8.80 million for the quarter, compared to analyst estimates of $9.13 million. Inovio Pharmaceuticals had a negative net margin of 208.92% and a negative return on equity of 66.07%. The company’s revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.35) EPS. sell-side analysts expect that Inovio Pharmaceuticals Inc will post -1.07 earnings per share for the current year.
Several research firms recently commented on INO. BidaskClub raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 24th. ValuEngine raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 24th. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, March 21st. Maxim Group set a $8.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday. Finally, Royal Bank of Canada increased their target price on shares of Inovio Pharmaceuticals from $11.00 to $14.00 and gave the company an “outperform” rating in a report on Thursday, March 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the stock. Inovio Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $19.07.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.